Literature DB >> 7586159

Mouse mammary hyperplasias and neoplasias exhibit different patterns of cyclins D1 and D2 binding to cdk4.

T K Said1, L Luo, D Medina.   

Abstract

Deregulated expression of G1 cyclins D1 and D2 is a feature of some neoplasias. This study examined the altered expression of D1 and D2 cyclins, both the total pool and as associated with cdk4 and cdk2, at different stages of mouse mammary tumorigenesis. Three different mammary hyperplastic outgrowth lines, TM2, TM10 and TM12, and their respective tumors were examined. Increasing levels of the cyclin D1 protein pool, D1 binding to cdk4 and cdk2 and cdk4 kinase activity were closely correlated with tumorigenesis. In constrast, cyclin D2 binding to cdk4 was predominant in hyperplasias and much less in tumors, where cyclin D1 became predominant. However, the cyclin D2 pool showed increases of 15-65 times in hyperplasias compared with normal gland and further increases of 11-15 times in two of three different tumors. The message level for cyclin D1 increased only 2-3 times in tumors compared with normal gland. Cyclin D2 mRNA was highest in normal tissue and decreased only marginally in tumors. These results suggest that cyclin D2 functions uniquely from cyclin D1 in the early stages of mouse mammary tumor development. Cyclin D2 bound to cdk4 may act to guarantee a low level of kinase activity in hyperplasias and may be an attempt to direct the mammary epithelial cells through differentiation rather than proliferation. This interaction may be one of the negative regulatory mechanisms in the early stages in mouse mammary tumor development, until cyclin D1 totally replaces cyclin D2 binding to cdk4, which would activate the high levels of cdk4 kinase activity observed in neoplasias.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7586159     DOI: 10.1093/carcin/16.10.2507

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  6 in total

Review 1.  Cell cycle genes in a mouse mammary hyperplasia model.

Authors:  Thenaa K Said; Daniel Medina
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-01       Impact factor: 2.673

2.  Amplification of CCND1 and expression of its protein product, cyclin D1, in ductal carcinoma in situ of the breast.

Authors:  J F Simpson; D E Quan; F O'Malley; T Odom-Maryon; P E Clarke
Journal:  Am J Pathol       Date:  1997-07       Impact factor: 4.307

Review 3.  Multistep mouse mammary tumorigenesis through pre-neoplasia to neoplasia and acquisition of metastatic potential.

Authors:  Airo Tsubura; Katsuhiko Yoshizawa; Norihisa Uehara; Takashi Yuri; Yoichiro Matsuoka
Journal:  Med Mol Morphol       Date:  2007-03-29       Impact factor: 2.309

Review 4.  Cyclins and breast cancer.

Authors:  E A Musgrove; R Hui; K J Sweeney; C K Watts; R L Sutherland
Journal:  J Mammary Gland Biol Neoplasia       Date:  1996-04       Impact factor: 2.673

5.  Overexpression of cyclin D1 in rat esophageal carcinogenesis model.

Authors:  E M Youssef; T Hasuma; Y Morishima; N Takada; H Osugi; M Higashino; S Otani; S Fukushima
Journal:  Jpn J Cancer Res       Date:  1997-01

6.  Increased expression of cyclin D1, cyclin E and p21(Cip1) associated with decreased expression of p27(Kip1) in chemically induced rat mammary carcinogenesis.

Authors:  T J Jang; M S Kang; H Kim; D H Kim; J I Lee; J R Kim
Journal:  Jpn J Cancer Res       Date:  2000-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.